New combo shot aims to reboot immune attack on tough lung cancers
NCT ID NCT07330596
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests a new drug, QL1706, which blocks two immune checkpoints (PD-1 and CTLA-4) at once, combined with standard chemotherapy for people with advanced non-small cell lung cancer that no longer responds to initial immunotherapy. About 96 adults whose tumors lack certain gene mutations will be randomly assigned to receive either the combo or chemo alone. The goal is to see if the combo can delay cancer growth better than chemo by itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui cancer hospital
RECRUITINGHefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.